Tesamorelin is the full 44-amino-acid GHRH sequence, modified to resist the enzyme (DPP-IV) that destroys native GHRH within minutes. Unlike exogenous HGH — which bypasses the pituitary and delivers a flat bolus of hormone — tesamorelin stimulates your own GH release in the same pulsatile pattern your body uses during deep sleep. The somatostatin brake stays intact, making supraphysiological spikes mechanistically difficult.
The FDA approved it in 2010 based on two Phase III trials totaling 816 patients — the only GH secretagogue with that level of clinical proof. The results: 15–20% visceral fat reduction versus placebo over 26 weeks, with improvements in triglycerides, waist circumference, and liver fat. For context: sermorelin's adult body composition data comes from 19 subjects. CJC-1295 without DAC has zero published human trials. The evidence gap between tesamorelin and everything else in this class is structural.
One caveat that matters: the fat comes back. Patients who stopped at 26 weeks regained 24.5% of their visceral fat by week 52, nearly erasing six months of benefit. This is an ongoing intervention, not a reset.
| At a Glance | |
|---|---|
| Dosage | 1–2 mg subcutaneous (injected under the skin), nightly. |
| Protocol | 12–16 weeks on, 2–4 weeks off. 30–60 minutes before bed, at least 2 hours fasted. |
| Results timeline | Body composition changes become measurable by weeks 4–6, with 15–20% visceral fat reduction documented over 26-week Phase III trials. |
| Side effects | Injection site reactions are the most common (30–51% in trials), followed by fluid retention that can manifest as puffy fingers or carpal-tunnel-like tingling, and mild muscle aches that typically resolve in the first weeks. |
| Regulatory status | FDA-approved for HIV-associated lipodystrophy (Egrifta, 2010). Off-label for body recomposition. WADA-prohibited. |
| Best stacked with | GLP-1 agonists — GLP-1 drives fat loss, tesamorelin preserves lean mass. AOD-9604 for additional visceral fat targeting. |
What Is Tesamorelin?
The tesamorelin peptide consists of the full 44-amino-acid GHRH sequence -- a synthetic analog of growth hormone-releasing hormone, the natural signaling molecule your hypothalamus uses to tell your pituitary gland to produce growth hormone. It has a small chemical modification (a trans-3-hexenoic acid group) attached to protect it from rapid enzymatic breakdown. The FDA approved it in November 2010 under the brand name Egrifta for one specific use: reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy¹ ².
What makes this compound different from injecting growth hormone directly is a distinction that matters more than most people realize. Tesamorelin does not add growth hormone to your system from the outside. Instead, it stimulates your own pituitary gland to release growth hormone in the same pulsatile pattern your body uses naturally. Think of it as turning up the volume on a signal your body already sends, rather than replacing the signal entirely with an external source.
This preservation of natural pulsatility -- the rhythmic on-off pattern of GH release -- is not just a pharmacological curiosity. It is central to why the compound has a different safety profile than exogenous growth hormone, and why it cannot easily push GH levels into dangerous territory. The body's built-in brake system (somatostatin negative feedback) still works when you use tesamorelin. When GH and IGF-1 rise, somatostatin increases and suppresses further release³. That brake does not exist when you inject recombinant GH directly.
How Tesamorelin Works
Tesamorelin works by binding to GHRH receptors on cells in the anterior pituitary called somatotrophs, triggering the cAMP/PKA signaling pathway that leads to growth hormone synthesis and release. This is the same mechanism your own GHRH uses. The trans-3-hexenoic acid modification protects it from DPP-IV (an enzyme that rapidly degrades native GHRH), giving it a modestly longer working window than unmodified GHRH² ⁴.
Despite that protection, the drug is still short-lived in the bloodstream. Its half-life ranges from about 8 minutes in healthy subjects to roughly 38 minutes at steady state in HIV patients². Subcutaneous (injected under the skin) bioavailability is remarkably low -- less than 4%². It works not because it lingers in your blood, but because the brief receptor activation it produces is potent enough to trigger a full downstream GH cascade.
Here is what that cascade looks like in practice:
Step 1: Pituitary Activation. Tesamorelin binds GHRH receptors, triggering a burst of GH release that mimics your body's natural nocturnal GH pulses.
Step 2: IGF-1 Production. The released GH travels to the liver and other tissues, stimulating production of IGF-1 (insulin-like growth factor 1) -- the molecule that mediates most of GH's downstream effects on muscle, fat, and tissue repair.
Step 3: Metabolic Shift. Elevated GH and IGF-1 shift the body's metabolic bias toward lipolysis (fat breakdown), particularly in visceral fat tissue, while enhancing protein synthesis and nitrogen retention in muscle. This is why the compound preferentially targets belly fat rather than producing general weight loss¹ ⁵.
Step 4: Feedback Regulation. As GH and IGF-1 levels rise, the hypothalamus increases somatostatin release, which acts as a ceiling on further GH secretion. This feedback loop is preserved with tesamorelin -- a critical safety feature that prevents the runaway GH elevation possible with exogenous HGH³.
The net effect is a metabolic environment that favors visceral fat mobilization and lean tissue preservation -- not through forcing supraphysiological hormone levels, but by restoring the natural GH signaling that tends to decline with age, chronic illness, and prolonged caloric restriction.
What the Clinical Evidence Shows
The tesamorelin benefits documented in Phase III trials represent the strongest evidence base of any growth hormone secretagogue, anchored by two large randomized controlled trials involving a combined 816 patients. These were not small pilot studies or retrospective chart reviews -- they were the gold-standard double-blind, placebo-controlled trials that the FDA requires before approving a drug¹ ² ⁶.
This distinction matters because it separates tesamorelin from virtually every other peptide in the GH secretagogue space. Sermorelin's adult body composition data comes from a single trial of 19 people⁷. CJC-1295 without DAC has zero published human trials. The most popular clinical combination -- CJC-1295 no-DAC plus ipamorelin -- has never been studied as a paired protocol in any peer-reviewed trial⁸. Tesamorelin stands alone in having the kind of evidence that normally separates pharmaceutical drugs from research compounds.
The Phase III Trials
LIPO-010 (N=412) and CTR-1011 (N=404) were both double-blind, placebo-controlled trials using 2:1 randomization (two patients received the drug for every one on placebo). Patients received 2 mg daily via subcutaneous injection. The primary endpoint was percent change in visceral adipose tissue (VAT) measured by CT scan at 26 weeks² ⁶.
Both trials met their primary endpoint decisively:
- LIPO-010: Least-squares mean VAT reduction of -19.6% versus placebo (95% CI: -23.7% to -15.3%)⁶
- CTR-1011: Least-squares mean VAT reduction of -11.7% versus placebo (95% CI: -16.2% to -7.1%)⁶
Waist circumference also decreased significantly: -1.8 cm in LIPO-010 and -1.3 cm in CTR-1011 versus placebo⁶. IGF-1 levels increased by approximately 106-109 ng/mL in the treatment groups, confirming the expected pharmacological effect¹ ⁴.
These are not marginal results. A 12-20% preferential reduction in visceral fat -- the deep belly fat wrapped around your organs that drives metabolic disease risk -- is a clinically meaningful outcome, particularly because it occurred without significant changes in subcutaneous fat (the fat under your skin that you can pinch)⁵.
Extension Data: 26-52 Weeks
The trials included an extension phase from weeks 26 through 52. Patients who continued on the compound maintained their VAT reduction with an additional -1.4% change. Those switched to placebo regained fat rapidly -- but the precise dynamics of that regain are important enough to warrant their own section below².
Beyond HIV: Liver Fat and Metabolic Health
The clinical program extended beyond visceral fat measurement. A randomized trial in HIV patients with MRI-confirmed non-alcoholic fatty liver disease (NAFLD) showed that tesamorelin reduced hepatic fat fraction (the amount of fat stored in the liver) and improved histologic features on biopsy, including reduced steatosis and slowed fibrosis progression⁵. This reframes this peptide as more than a cosmetic fat-redistribution tool -- in the right population, it appears to have genuine liver-disease-modifying potential.
Additional studies in abdominally obese adults with reduced GH and in patients with established type 2 diabetes showed improvements in visceral adiposity and cardiometabolic markers without catastrophic deterioration of glucose control⁵ ⁹. These studies are smaller and less definitive than the Phase III HIV trials, but they suggest the mechanism of action is relevant beyond the specific population it is approved for.
An important caveat: all of the large, rigorous evidence comes from HIV-associated lipodystrophy. Every other application -- general body composition, anti-aging, recomposition during caloric restriction -- represents off-label extrapolation from this evidence base. The mechanism is sound, the adjacent data are encouraging, but the level of proof is fundamentally different.
Visceral Fat Reduction: The Specific Numbers
For those researching tesamorelin for belly fat specifically, the data are clear: this compound reduces visceral adipose tissue by 12-20% versus placebo over 26 weeks at a dose of 2 mg daily, as demonstrated in two Phase III RCTs totaling 816 HIV patients with lipodystrophy. This reduction is specific to visceral fat, with minimal effect on subcutaneous fat, and is accompanied by improvements in triglycerides and waist circumference¹ ² ⁶.
Here is what the specific numbers look like across the clinical program:
| Outcome | LIPO-010 (N=412) | CTR-1011 (N=404) |
|---|---|---|
| VAT reduction vs placebo | -19.6% (CI: -23.7% to -15.3%) | -11.7% (CI: -16.2% to -7.1%) |
| Waist circumference change | -1.8 cm vs placebo | -1.3 cm vs placebo |
| IGF-1 increase | ~106-109 ng/mL | ~106-109 ng/mL |
| Triglyceride improvement | Statistically significant | Statistically significant |
The difference between the two trials (19.6% vs 11.7%) likely reflects population variability rather than any change in the drug itself. Both results were statistically significant and clinically meaningful.
Why does tesamorelin target visceral fat specifically? The answer lies in how growth hormone interacts with different fat depots. Visceral adipocytes (fat cells deep in the abdomen, wrapped around organs) have a higher density of GH receptors and are more responsive to GH-stimulated lipolysis than subcutaneous fat cells⁵. When it raises GH levels, visceral fat gets hit harder -- not because the compound is somehow "targeted," but because that fat tissue is inherently more sensitive to the GH signal.
This specificity is actually a significant advantage. Visceral fat is the metabolically dangerous kind -- it is more strongly associated with insulin resistance, cardiovascular disease, inflammatory markers, and liver disease than subcutaneous fat⁵. A compound that preferentially reduces visceral fat delivers outsized metabolic health benefits relative to its effect on the bathroom scale. You might not see dramatic weight loss, but the fat you are losing is the fat that matters most for long-term health.
The Catch: What Happens When You Stop
Tesamorelin's visceral fat reduction is not permanent. In the Phase III extension data, patients who stopped treatment at 26 weeks and switched to placebo regained an average of 24.5% of their visceral fat by week 52, while those who continued maintained their reduction with an additional -1.4% loss. The difference between the two groups was -25.8% (P=0.0008)².
This is the finding that honest discussions of this compound cannot skip over -- and that most marketing materials conveniently omit.
The fat comes back. Not slowly, not partially -- it comes back aggressively. Patients who discontinued did not just plateau; they actively regained visceral fat at a pace that nearly erased the six months of treatment benefit. This has direct practical implications: tesamorelin is not a "course of treatment" that resets your metabolism and then lets you maintain results independently. It is, based on the available data, a compound that requires continuous use to sustain its effects.
Think of it like a thermostat. The drug adjusts the set point of your visceral fat metabolism while you are using it. The moment you turn off the thermostat, the system drifts back toward its previous setting. Your body has not "learned" a new baseline -- it has been temporarily overridden.
This does not make tesamorelin useless. It means that realistic expectations require understanding it as an ongoing intervention, not a one-time fix. For someone with HIV-associated lipodystrophy (the approved use), continuous therapy may be clinically justified. For someone exploring off-label use for body composition, this finding changes the cost-benefit calculation considerably.
Why It Matters for GLP-1 Users
GLP-1 agonists drive fat loss but provide no anabolic protection. Studies show 25–40% of weight lost on GLP-1s can be lean mass.
| What GLP-1s Provide | What Tesamorelin Provides |
|---|---|
| Appetite suppression | GH pulsatility restoration |
| Fat loss driver | Lean mass preservation |
| Glucose control | Nitrogen retention during deficit |
GLP-1s create the deficit. Tesamorelin protects what you don't want to lose.
The timing logic: GLP-1 effects peak during waking hours (mobilization, activity). Tesamorelin-driven GH pulses peak during sleep (repair, protein synthesis). Day for breakdown, night for protection.
Dosing
Reconstitution note: Use bacteriostatic water with sodium chloride (isotonic) to reduce injection site sting and prevent welts. Use the reconstitution calculator to determine exact volumes.
| Dose | 1–2 mg |
| Route | Subcutaneous (abdomen or thigh) |
| Timing | 30–60 min before bed, 2+ hours fasted |
| Cycle | 12–16 weeks on, 2–4 weeks off |
Titration:
| Phase | Dose | Duration |
|---|---|---|
| Start | 1 mg nightly | 2–4 weeks |
| Increase | 2 mg nightly | If needed after 2–3 weeks |
| Adjust | EOD dosing | If IGF-1 runs high or side effects |
Week 8 checkpoint: Get IGF-1 labs. Target physiologic elevation (high-normal), not supraphysiologic. If IGF-1 exceeds 350–400 ng/mL, reduce dose.
GLP-1 + Tesamorelin Protocol
GLP-1 agonist: Weekly injection per standard protocol
Tesamorelin: 1–2 mg SC, 30–60 min before bed
Resistance training: 3–4× per week
Protein: 1.6–2.2 g/kg body weightThe GLP-1 handles appetite. Tesamorelin handles hormonal support. Training provides stimulus. Protein provides building blocks.
Side Effects and Safety Profile
Tesamorelin's side effect profile in the Phase III trials was generally manageable. The most common adverse events were injection site reactions (30-51% tesamorelin vs 21-24% placebo), myalgia or muscle pain (4-8% vs 2%), and fluid retention or edema (5-10% vs 1-6%). Serious adverse event rates were similar between treatment and placebo groups⁶.
Here is what to know about each:
Injection site reactions were the most frequently reported issue and are typical of any subcutaneous peptide injection -- redness, mild pain, or itching at the injection site. These are generally manageable with proper injection technique and site rotation.
Fluid retention and edema deserve more attention. GH-axis stimulation increases sodium and water retention -- this is a class effect shared by all compounds that raise GH levels, including exogenous HGH. In practice, this can manifest as puffy fingers, mild ankle swelling, or carpal-tunnel-like tingling in the hands. These effects are typically dose-related and resolve with dose reduction or discontinuation⁵.
Glucose metabolism is the area that requires the most careful monitoring. The FDA flagged a higher glucose intolerance risk across the overall development program, even though the individual pivotal trials did not show statistically significant glycemic deterioration¹ ⁶. GH is inherently diabetogenic -- it promotes insulin resistance as a normal part of its metabolic function. In the Phase III trials, this did not reach a clinically significant threshold for most patients. But for anyone with pre-existing insulin resistance, prediabetes, or type 2 diabetes, glucose monitoring during use is not optional.
A safety trial specifically in type 2 diabetic patients showed no major worsening of HbA1c or fasting glucose, which is reassuring but not a blanket clearance⁹. The conservative approach: check fasting glucose and HbA1c at baseline and at regular intervals during use.
IGF-1 elevation is expected and is central to how tesamorelin works. IGF-1 levels increased by approximately 106-109 ng/mL across trials¹ ⁴. No malignancy signal appeared during the trial windows (up to 52 weeks), but IGF-1's known role in cell proliferation means that active cancer or high neoplasm risk is considered a contraindication. IGF-1 monitoring is recommended to keep levels within the physiologic "high-normal" range rather than pushing into acromegalic territory.
What the data do NOT show: There was no signal for increased cardiovascular events, no liver toxicity, and no HPTA (hypothalamic-pituitary-testicular axis) suppression -- a meaningful distinction from exogenous testosterone or anabolic steroids² ⁶.
Injection Site Reactions: What to Expect
Tesamorelin injection site reactions follow a specific pattern that catches many users off guard: they develop over time, not immediately.
The Histamine Response
Unlike peptides that burn due to pH (like NAD+), tesamorelin triggers a histamine-mediated reaction. The peptide activates mast cells in subcutaneous tissue, releasing histamine that causes:
- Itchy, raised welts ("mosquito bite" appearance)
- Localized redness and warmth
- Mild swelling around the injection site
This is an immune response, not an allergic reaction. It's dose-related and site-dependent.
Progressive Sensitization Timeline
Most users report no issues initially, then progressive reactions:
| Timeframe | Typical Experience |
|---|---|
| Weeks 1–3 | Minimal or no reaction. Users assume they're "fine" |
| Weeks 4–5 | First noticeable welts appear. Often dismissed as technique |
| Weeks 6–8 | Reactions become consistent. Some sites worse than others |
| Weeks 8+ | Pattern stabilizes. Mitigation strategies become necessary |
This progressive onset is why "rotate sites" advice feels inadequate — you rotated from the start, but reactions appeared anyway. The tissue is sensitizing to repeated tesamorelin exposure, not to injection trauma.
Mitigation Strategies
1. Pre-dose antihistamines
Taking an H1 blocker 30–60 minutes before injection reduces histamine response:
- Cetirizine (Zyrtec) 10mg — non-drowsy, long-acting
- Loratadine (Claritin) 10mg — alternative if cetirizine causes drowsiness
- Diphenhydramine (Benadryl) 25mg — stronger but sedating; use if injecting before bed anyway
Most users find antihistamines reduce reaction severity by 50–70%. Some eliminate welts entirely.
2. Deeper injection technique
Shallow SubQ (just under the skin) puts tesamorelin in close contact with mast cell-rich tissue. Deeper injection reduces this:
- Use a ½" needle and inject at 90° angle
- Pinch skin firmly to create depth
- Aim for the fat pad, not just subcutaneous space
- Some users switch to IM (outer thigh) if SubQ reactions persist
3. Site selection
Not all sites react equally. Based on r/Peptides reports:
| Site | Reaction Severity | Notes |
|---|---|---|
| Lower abdomen | Higher | Dense mast cell population |
| Upper abdomen | Moderate | Better than lower |
| Love handles | Lower | Often the best-tolerated site |
| Outer thigh | Variable | Some users tolerate well; others worse |
Find your least-reactive zone and rotate within it rather than across your whole body.
4. Adding extra BAC water
Diluting the injection volume reduces local concentration. If you're using 1mL per dose, try 1.5–2mL. The larger volume spreads tesamorelin across more tissue, reducing the histamine trigger at any single point.
5. Slow injection speed
Rapid injection creates a bolus that triggers stronger mast cell activation. Inject over 30–60 seconds instead of 5–10 seconds.
When Reactions Are Concerning
Typical tesamorelin reactions are localized and resolve within 1–2 hours. Seek medical attention if:
- Welts spread beyond the injection site
- You develop hives on other body areas
- Facial swelling, throat tightness, or difficulty breathing (anaphylaxis — rare but serious)
- Reactions intensify significantly week-over-week despite mitigation
- Injection sites become hard, hot, or develop pus (infection, not histamine)
If you're experiencing severe reactions that don't respond to antihistamines and technique changes, discuss with your provider. Some individuals are simply sensitive to tesamorelin and may need to discontinue or try alternative GHRH analogs.
Monitoring
| Timepoint | Tests |
|---|---|
| Baseline | IGF-1, fasting glucose, HbA1c, lipids |
| Week 8 | IGF-1 (critical decision point) |
| Ongoing | Symptoms; glucose if at-risk |
Who Should Consider Tesamorelin
Good candidates:
- Training adults with central adiposity
- GLP-1 users concerned about muscle loss
- Those with documented NAFLD
- Willing to work with provider and do bloodwork
Not good candidates:
- Active cancer (IGF-1 contraindicated)
- Uncontrolled diabetes
- Those seeking quick fix without training foundation
- WADA athletes (prohibited)
Tesamorelin vs HGH
Tesamorelin and recombinant human growth hormone (HGH) both increase GH and IGF-1 levels, but they do so through fundamentally different mechanisms that produce meaningfully different risk profiles. Tesamorelin stimulates your own pituitary to release GH in natural pulses; HGH bypasses the pituitary entirely and delivers a continuous bolus of exogenous hormone³.
This distinction plays out in three important ways:
1. Pulsatility vs. Continuous Elevation
Your body naturally releases GH in discrete pulses -- concentrated bursts followed by return-to-baseline troughs, with the largest pulses occurring during deep sleep. This pulsatile pattern is not just how GH is delivered; it is how your tissues are designed to respond. Receptors that see constant GH stimulation behave differently (and often worse) than receptors that see rhythmic pulses.
Tesamorelin preserves this pulsatile architecture³. HGH injections, depending on dose and timing, tend to produce a sustained elevation that flattens the natural rhythm. This is analogous to the difference between a natural sunrise gradually waking you up versus someone flipping all the lights on at once -- the end result (you are awake) is similar, but the physiological experience is not identical.
2. The Somatostatin Brake
When tesamorelin stimulates GH release, the resulting rise in GH and IGF-1 triggers increased somatostatin production, which suppresses further GH release³. This negative feedback loop creates a built-in ceiling that makes it difficult to achieve dangerously supraphysiological GH levels with this peptide alone.
HGH bypasses this brake entirely. The exogenous hormone enters circulation regardless of what your feedback systems are doing. This is why HGH use at higher doses can produce acromegalic features (enlarged jaw, hands, feet), insulin resistance, and other consequences of GH excess -- side effects that are mechanistically difficult to produce with tesamorelin.
3. Practical Differences
| Feature | Tesamorelin | HGH |
|---|---|---|
| Mechanism | Stimulates endogenous GH release | Provides exogenous GH directly |
| GH pattern | Pulsatile (physiologic) | Sustained elevation |
| Feedback preserved | Yes (somatostatin brake intact) | No (bypasses feedback) |
| Risk of GH excess | Low (self-limiting) | Dose-dependent (can be significant) |
| FDA status | Approved (HIV lipodystrophy) | Approved (multiple indications) |
| Evidence for VAT | Phase III RCTs (N=816) | Limited for VAT specifically |
| Relative cost | Lower than brand HGH | High (brand); variable (compounded) |
The tradeoff is potency versus safety margin. HGH can achieve higher peak GH levels and may be more effective for severe GH deficiency. Tesamorelin requires a functioning pituitary to work at all -- if the pituitary cannot produce GH (as in structural pituitary damage), it will not help. But for the majority of people whose pituitary function is intact and whose goal is optimizing rather than replacing GH signaling, this peptide offers a more physiologic approach with a wider safety margin.
For a broader comparison of GH-stimulating peptides, including how sermorelin and ipamorelin fit into this landscape, see our GH secretagogue comparison guide.
Regulatory Status and Access
Tesamorelin is FDA-approved under the brand name Egrifta specifically for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It was approved in November 2010 and is the only GH secretagogue with current FDA approval for a therapeutic (non-diagnostic) indication¹ ². Any use outside of HIV-associated lipodystrophy is off-label.
The regulatory story here is straightforward compared to other peptides in this space. Unlike sermorelin (which was FDA-approved in 1997 but commercially withdrawn in 2008), tesamorelin has a currently marketed branded product. Unlike CJC-1295 and ipamorelin (which exist in regulatory limbo -- not banned, not approved, not explicitly cleared for compounding), its FDA approval provides a clear legal and medical foundation¹⁰.
In practice, access works through several channels:
Branded (Egrifta/Egrifta SV): Available by prescription for the approved indication. Expensive without insurance coverage, which is typically limited to the HIV lipodystrophy indication.
Compounding pharmacies: The compound is available through compounding pharmacies, often at significantly lower cost than the branded product. The FDA-approved status of the molecule provides a legal framework for compounding, though compounding pharmacies producing it may face brand-holder objections.
Practitioner types: Endocrinologists, functional medicine practitioners, and peptide-focused clinicians are the most common prescribers for off-label use.
WADA status: Tesamorelin is prohibited in competitive sport under the World Anti-Doping Agency's banned substance list. Athletes subject to drug testing should be aware that any GH secretagogue use will result in an anti-doping violation.
FAQ
Is tesamorelin the same as HGH?
No. Tesamorelin stimulates your pituitary to release its own GH in natural pulses. HGH replaces your production with synthetic hormone.
How long to see results?
Sleep quality improves in 1–2 weeks. Strength stabilizes by weeks 3–6. Body composition changes consolidate by week 8–12.
Can you take it with semaglutide?
Yes. They work on different axes and are complementary. GLP-1 drives fat loss; tesamorelin provides anabolic support.
What time of day?
30–60 min before bed, at least 2 hours after eating. Aligns with natural nocturnal GH secretion.
What are the side effects of tesamorelin?
The most common side effect is fluid retention (edema), which is dose-related and reversible. Some people experience tingling or numbness in the hands (carpal tunnel-like symptoms)—reducing the dose usually resolves this. Injection site reactions are common and often develop progressively over weeks 4–8; see the detailed injection reactions section for mitigation strategies. Joint and muscle aches are usually transient in the first weeks. Serious side effects are rare at physiologic doses.
What is the recommended tesamorelin dosage and protocol?
Tesamorelin is injected subcutaneously at 1–2 mg nightly, 30–60 minutes before bed on at least a 2-hour fast. Start at 1 mg for the first 2–3 weeks, then increase to 2 mg if needed and tolerated. Check IGF-1 levels at week 8 — if they exceed 350–400 ng/mL, reduce the dose or switch to every-other-day dosing. Standard cycles run 12–16 weeks on, 2–4 weeks off. Cycling preserves pituitary sensitivity and prevents sustained IGF-1 elevation — unlike exogenous HGH, tesamorelin works through your own axis, so breaks let the system reset naturally.
Does tesamorelin need to be cycled or can I take it continuously?
Yes — tesamorelin must be cycled. Standard protocols run 12–16 weeks on, followed by 2–4 weeks off. Cycling preserves pituitary sensitivity and prevents sustained IGF-1 elevation. Unlike exogenous HGH, tesamorelin works through your own GH axis — breaks allow the system to reset naturally. Some practitioners use shorter on-cycles (8 weeks) with longer breaks. Running tesamorelin continuously risks desensitizing the pituitary and losing the physiologic pulsatile GH pattern that makes it safer than synthetic HGH.
What blood tests should I monitor on tesamorelin?
At minimum: IGF-1 at baseline and week 8 (the critical decision point for dose adjustment). Also check fasting glucose, HbA1c, and lipid panel at baseline. If you're at risk for diabetes, monitor glucose more frequently—small shifts are possible. IGF-1 is the key marker: you want it in the high-normal range, not supraphysiologic.
Can tesamorelin help with belly fat?
Yes—this is its primary clinical indication. Studies show 15–20% reduction in visceral adipose tissue (VAT) over 26 weeks. Tesamorelin specifically targets visceral fat, the metabolically dangerous fat around organs, while preserving lean mass. It's FDA-approved for HIV lipodystrophy specifically because of this visceral fat reduction effect.
How do I reconstitute and store tesamorelin?
Reconstitute with bacteriostatic water containing sodium chloride (isotonic) to reduce injection site reactions. Inject water slowly against the vial wall, then gently swirl—don't shake. Store unreconstituted powder refrigerated. Once reconstituted, keep at 2–8°C and use within 28 days. Protect from light. The commercial Egrifta formulation comes with specific diluent and instructions.
Is tesamorelin legal?
Yes, with a prescription. Tesamorelin (brand name Egrifta) is FDA-approved for HIV-associated lipodystrophy. For other uses (recomposition, anti-aging), it's prescribed off-label. It's also available through compounding pharmacies. However, it's prohibited by WADA for competitive athletes. For non-athletes with a prescription, there are no legal restrictions.
Who shouldn't take tesamorelin?
Active cancer or history of cancer is the main contraindication—IGF-1 elevation can promote tumor growth. Uncontrolled diabetes requires caution since GH affects glucose metabolism. Pregnant or nursing women should avoid it. People with pituitary disorders may not respond normally. Anyone unwilling to do bloodwork and work with a provider shouldn't use it—IGF-1 monitoring is essential, not optional.
Tesamorelin for Injury Recovery
Connective tissue doesn't rebuild on your schedule—it rebuilds during sleep. GH pulses during slow-wave sleep trigger IGF-1 production, which drives collagen synthesis and tissue consolidation. When this rhythm is disrupted (from pain, poor sleep, chronic stress, or injury itself), tissue can be structurally repaired but never fully consolidates.
This is the "almost healed, but keeps flaring" pattern. Progress for a few weeks, then mystery regression. The injury site is warm and supple, but strength plateaus 10–15% below baseline. Sleep feels unrefreshed despite adequate hours.
Tesamorelin is a GHRH (Growth Hormone Releasing Hormone) analog that restores nocturnal GH pulsatility—amplifying your body's own sleep-timed repair signals rather than replacing them with exogenous hormone.
| Injury Recovery At a Glance | |
|---|---|
| What it is | Synthetic GHRH(1-44) analog |
| Mechanism | Restores pulsatile, nocturnal GH secretion |
| Primary effect | Sleep-timed tissue repair; IGF-1-driven collagen synthesis |
| Dose | 1–2 mg subcutaneous, 30–60 min before sleep |
| Cycle | 8–12 weeks |
| When to add | Sleep disrupted; recovery unpredictable; strength plateaued despite good structural repair |
Key principle: Tesamorelin is not a healing peptide—it's a timing peptide. It makes existing repair consolidate during sleep instead of oscillating unpredictably.
Who Should Use Tesamorelin for Injury Recovery
Use Tesamorelin If
- Sleep is choppy, dreams are flat, or you wake unrefreshed
- Recovery feels "random"—good days followed by mystery flares
- Strength has plateaued 10–15% below baseline despite solid rehab
- Structural repair looks good (tissue warm, supple) but consolidation isn't sticking
- You're running a base protocol (BPC-157, TB-500) and need the next layer
Skip Tesamorelin If
- Tissue is still cold, stiff, or poorly perfused → Need more BPC-157/TB-500
- Energy crashes even at rest → Need NAD+ first
- Pain is clearly structural (not recovery-timing related)
- You haven't tried improving sleep hygiene first
- Active malignancy or proliferative retinopathy (contraindicated)
Do I Need the Base Protocol First?
Recommended but not required. Tesamorelin works best when layered on top of foundational repair:
| Scenario | Recommendation |
|---|---|
| Acute injury (<4 weeks) | Start with BPC-157 + TB-500 |
| Chronic injury with multiple bottlenecks | Start with 5-compound base protocol |
| Sleep/recovery timing is the clear limiter | Tesamorelin can be added earlier |
| Already running base protocol, sleep issues persist | Add Tesamorelin |
Tesamorelin amplifies repair that's already possible. If tissue lacks blood flow (needs BPC-157), cellular mobility (needs TB-500), or energy (needs NAD+), there's less to amplify. But if structural repair is progressing and sleep-timed consolidation is the bottleneck, Tesamorelin addresses that directly.
How Tesamorelin Works for Injury Recovery
The Problem: Disrupted GH Pulsatility
Growth hormone isn't released continuously—it pulses, primarily during slow-wave (deep) sleep. Each pulse triggers hepatic IGF-1 production, which drives:
- Collagen synthesis
- Protein anabolism
- Tissue repair consolidation
When this pulsatile pattern is disrupted (common with chronic pain, poor sleep, stress, or injury), repair becomes unpredictable:
| Normal GH Pattern | Disrupted GH Pattern |
|---|---|
| Strong nocturnal pulses | Flattened, irregular release |
| IGF-1 peaks during sleep | Variable, inconsistent IGF-1 |
| Collagen synthesis overnight | Erratic tissue turnover |
| Predictable recovery | "Two steps forward, one step back" |
What Tesamorelin Does
Tesamorelin is a GHRH analog—it binds pituitary GHRH receptors and triggers your own GH release in natural pulses. Unlike exogenous HGH (which provides constant, flat-line hormone), tesamorelin preserves circadian rhythm and endogenous feedback.
| Pathway | Effect | What You Notice |
|---|---|---|
| Nocturnal GH pulse amplification | Deeper, more consistent GH peaks during slow-wave sleep | More restorative sleep; waking less stiff |
| IGF-1 production | Sustained IGF-1 for tissue synthesis | Tendons and muscles rebuild "overnight" |
| Sleep architecture support | GH pulses reinforce slow-wave sleep | Fewer night wakings |
| Collagen turnover | Organized, predictable remodeling | Progress sticks; fewer mystery flares |
Optional: Adding Ipamorelin
Ipamorelin is a ghrelin receptor agonist that extends the GH pulse window without spiking cortisol. It works synergistically with Tesamorelin:
- Tesamorelin provides the GHRH signal that initiates the GH pulse
- Ipamorelin reduces somatostatin brake and extends pulse duration
| Add Ipamorelin If | Skip Ipamorelin If |
|---|---|
| Tesamorelin alone for 4+ weeks without expected improvement | Tesamorelin is working well |
| Higher-burden recovery (severe injury, high training load) | First cycle; want to assess Tesamorelin response |
| Need extended GH window | Concerned about IGF-1 elevation |
Evidence Note: There are no clinical trials specifically testing Tesamorelin + Ipamorelin for injury recovery. The combination is based on Tesamorelin monotherapy trials, Ipamorelin pharmacology studies, and classical GHRH + GHS synergy physiology. Treat the combination as mechanistically plausible but not directly validated.
Injury Recovery Dosing Protocol
| Compound | Dose | Frequency | Route | Timing | Notes |
|---|---|---|---|---|---|
| Tesamorelin | 1–2 mg | Nightly | SubQ | 30–60 min before sleep | 2+ hours after last meal |
| Ipamorelin (optional) | 200–500 mcg | Nightly | SubQ | With Tesamorelin | Add after 4 weeks if needed |
Titration
| Phase | Dose | Duration |
|---|---|---|
| Start | 1 mg nightly | 2–4 weeks |
| Increase | 1.5–2 mg nightly | If needed after 2–3 weeks |
| Adjust | EOD dosing | If IGF-1 runs high or side effects |
Implementation Notes
- Timing is critical: Inject at least 2 hours after your last meal (carbs and fats blunt GH release)
- 30–60 minutes before sleep is optimal to align with slow-wave stages
- Check IGF-1 at weeks 4 and 8 to keep levels physiologic (high-normal, not supraphysiologic)
- Can co-inject Tesamorelin + Ipamorelin in the same syringe
- Do NOT mix with NAD+ (pH incompatible)
Injury Recovery Timeline
Weeks 1–2
- What's happening: GH timing beginning to consolidate
- What you notice: More restorative sleep; waking less stiff
- Challenge: Stay consistent; effects are subtle at first
Weeks 2–4
- What's happening: IGF-1 production stabilizing; collagen turnover becoming predictable
- What you notice: Fewer "mystery flares" after rehab
- Decision point: If not improving, verify timing and consider adding Ipamorelin
Weeks 4–8
- What's happening: Sleep architecture and nocturnal anabolism stable
- What you notice: Recovery predictable; strength gains stick
- Lab check: IGF-1 at week 4 and 8; adjust dose if supraphysiologic
Weeks 8–12
- What's happening: Tissue consolidation; strength approaching baseline
- What you notice: Progress continues without regression
- Decision point: Continue, taper, or transition to maintenance
Signs Tesamorelin Is Working
- Restorative sleep stable ≥2 weeks
- Waking less stiff; dreams more vivid
- Recovery becomes predictable (fewer mystery flares)
- Strength gains stick after rehab sessions
- No swelling after moderate/heavy sessions
If Issues Persist
If you've optimized GH timing but still experience relapse under load (progress then flare with increased training intensity), consider the SS-31 section for mitochondrial stability.
If neuropathic symptoms persist (burning, tingling, allodynia), consider the ARA-290 section for small-fiber nerve support.
Maintenance Options
After 8–12 weeks:
- Taper off if recovery goals met
- Periodic cycles (4–6 weeks every 6–12 months) for long-term resilience
- Reduced frequency (EOD or 3× weekly) for maintenance
Injury Recovery FAQ
What's the difference between Tesamorelin and HGH for injury recovery?
Tesamorelin stimulates your pituitary to release its own GH in natural, circadian-aligned pulses. HGH replaces your production with synthetic hormone in flat-line, non-pulsatile elevation. For injury recovery, Tesamorelin's preserved pulsatility and circadian alignment make it generally preferred.
How long until I notice something?
Sleep quality often improves in 1–2 weeks. Recovery predictability improves by weeks 3–4. Strength consolidation becomes apparent by weeks 6–8.
Do I need to fast before injection?
Yes. Inject at least 2 hours after your last meal. Carbohydrates and fats blunt GH release, reducing Tesamorelin's effectiveness.
Can I use Tesamorelin without BPC-157/TB-500?
Yes, if sleep timing is your clear bottleneck and structural repair is progressing. Tesamorelin works independently but is often more effective layered on foundational repair.
What if sleep doesn't improve on Tesamorelin?
- Verify timing (30–60 min before sleep, 2+ hours fasted)
- Check sleep hygiene basics (darkness, temperature, consistency)
- Consider adding Ipamorelin
- Rule out other causes (sleep apnea, chronic pain, anxiety)
- Check labs—if IGF-1 isn't rising, reassess source/storage
Can I use Ipamorelin without Tesamorelin?
You can, but they work better together. Tesamorelin provides the GHRH signal that initiates the GH pulse; Ipamorelin extends and amplifies it. Using Ipamorelin alone still produces GH release but without the same circadian synchronization.
Related Topics
- Sermorelin Guide — pioneer GHRH analog with unique legal position
- GH Secretagogue Comparison — evidence rankings for every GH peptide
- Semaglutide Guide — the GLP-1 benchmark
- Tirzepatide Guide — dual-agonist with better body composition
- AOD-9604 Guide — lipolytic fragment (pairs with tesamorelin)
- GLP-1 Comparison — compare all three
- Retatrutide Guide — triple-agonist investigational
- Retatrutide Recomp Protocol — protecting lean mass
- DSIP Guide — opens the deep sleep window where GH-driven repair happens
- BPC-157 Guide — Vascular repair layer often used alongside tesamorelin
- TB-500 Guide — Cellular mobility — base repair before GH-axis support
- NAD+ Guide — Cellular energy — distinct from histamine burn mechanism
- Reconstitution Guide — How to prepare tesamorelin with isotonic BAC water
- ARA-290 Guide — For neuropathic symptoms that persist after injury resolution
- SS-31 Guide — Mitochondrial support for load-related relapse
- GLOW & KLOW Protocol — Multi-bottleneck chronic injury protocol
References
¹ GHRH metabolic effects in HIV — Falutz J et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." New England Journal of Medicine. 2007;357(23):2359-2370. PubMed 18057338 DOI
² Pooled Phase III visceral fat reduction — Falutz J et al. "Effects of tesamorelin in HIV-infected patients with excess abdominal fat: pooled Phase 3 analysis." Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291-4304. PubMed 20554713 DOI
³ Sermorelin vs. adult GH insufficiency — Walker RF. "Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?" Clinical Interventions in Aging. 2006;1(4):307-308. PMC2699646
⁴ GH and tesamorelin in lipodystrophy — Bedimo R. "Growth hormone and tesamorelin in HIV-associated lipodystrophy." HIV/AIDS - Research and Palliative Care. 2011;3:69-79. PMC3218714
⁵ Visceral and liver fat reduction — Stanley TL et al. "Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation." Lancet HIV. 2019. See also: Metabolism 2014 (obese adults with reduced GH).
⁶ CADTH clinical review — CADTH Clinical Review Report: Tesamorelin (Egrifta). Ottawa: Canadian Agency for Drugs and Technologies in Health; 2016. NBK539127
⁷ Long-term GHRH in aging adults — Khorram O et al. "Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women." Journal of Clinical Endocrinology & Metabolism. 1997;82(5):1472-1479. PubMed 9141536
⁸ GH secretagogues in body composition — Sinha DK et al. "Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males." Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159. PMC7108996
⁹ Safety in type 2 diabetes — Clemmons DR et al. "Safety of tesamorelin in patients with type 2 diabetes." PLOS One. 2017. See also: Metabolism 2014 (obese adults).
¹⁰ Peptide compounding regulatory status — Frier Levitt. "Regulatory Status of Peptide Compounding in 2025." frierlevitt.com
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.